Resumo

APARICIO-HERNANDEZ, RM; SILVA-CUEVAS, MA; VILLABONA-RIVAS, I  e  YUSTE-GUTIERREZ, AM. Positive assessment of drugs: february, march and april 2023. Sanid. Mil. [online]. 2023, vol.79, n.2, pp.111-117.  Epub 05-Fev-2024. ISSN 1887-8571.  https://dx.doi.org/10.4321/s1887-85712023000200008.

The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency issued in February, March and April 2023, and considered of interest to healthcare professionals, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product.

Palavras-chave : Espironolactona (Qaialdo^®); Futibatinib (Lytgobi^®); Glofitamab (Columvi^®); Ivosidenib (Tibsovo/Tidhesco^®); Mavacamten (Camzyos^®); Mirikizumab (Omvoh^®); Niraparib/abiraterona acetate (Akeegar^®); Pegunigalsidasa alfa (Elfabrio^®); Pirtobrutinib (Jaypirca^®); Ruxolitinib (Opzelura^®); Sirolimus (Hyftor^®); Tiosulfato sódico (Pedmarqsi^®); Ublituximab (Briumvi^®); Vacuna Covid-19, Recombinant with adjuvant (Bimervax^®); Respiratory virus vaccine sincitial, Recombinant, Adjuvant (Arexvy^®); Vadadustat (Vafseo^®)..

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )